BioVie, Inc. (BIVI)
1.43
+0.05
(+3.62%)
USD |
NASDAQ |
Oct 30, 16:00
1.42
-0.01
(-0.70%)
Pre-Market: 20:00
BioVie Enterprise Value : 2.084M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 2.084M |
| October 29, 2026 | 1.707M |
| October 28, 2026 | 2.310M |
| October 27, 2026 | 2.159M |
| October 26, 2026 | 1.330M |
| October 23, 2026 | 0.6508M |
| October 22, 2026 | 0.9525M |
| October 21, 2026 | 0.8017M |
| October 20, 2026 | 0.6508M |
| October 19, 2026 | 1.631M |
| October 16, 2026 | 0.3491M |
| October 15, 2026 | -0.1789M |
| October 14, 2026 | 0.0474M |
| October 13, 2026 | 0.3491M |
| October 12, 2026 | 1.254M |
| October 09, 2026 | 1.782M |
| October 08, 2026 | 0.9525M |
| October 07, 2026 | 1.858M |
| October 06, 2026 | 2.159M |
| October 05, 2026 | 2.159M |
| October 02, 2026 | 2.310M |
| October 01, 2026 | 2.386M |
| September 30, 2026 | 2.763M |
| September 29, 2026 | 2.914M |
| September 28, 2026 | 2.914M |
| Date | Value |
|---|---|
| September 25, 2026 | 3.404M |
| September 24, 2026 | 3.442M |
| September 23, 2026 | 3.592M |
| September 22, 2026 | 3.592M |
| September 21, 2026 | 3.592M |
| September 18, 2026 | 3.442M |
| September 17, 2026 | 4.724M |
| September 16, 2026 | 4.271M |
| September 15, 2026 | 4.498M |
| September 14, 2026 | 6.760M |
| September 11, 2026 | 5.855M |
| September 10, 2026 | 5.704M |
| September 09, 2026 | 6.157M |
| September 08, 2026 | 6.911M |
| September 04, 2026 | 6.383M |
| September 03, 2026 | 6.610M |
| September 02, 2026 | 6.610M |
| September 01, 2026 | 8.193M |
| August 31, 2026 | 8.495M |
| August 28, 2026 | 7.59M |
| August 27, 2026 | 7.816M |
| August 26, 2026 | 7.213M |
| August 25, 2026 | 7.062M |
| August 24, 2026 | 7.439M |
| August 21, 2026 | 6.006M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 556.15M |
| Amgen, Inc. | 295.24B |
| Anika Therapeutics, Inc. | 267.21M |
| BioCryst Pharmaceuticals, Inc. | 2.646B |
| Imunon, Inc. | 5.227M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.646M |
| Total Expenses (Quarterly) | 5.646M |
| EPS Diluted (Quarterly) | -0.7485 |
| Earnings Yield | -223.6% |
| Normalized Earnings Yield | -223.59 |